Streetbeat News

Price Targets

CRSP

TD Cowen analyst Tyler Van Buren has downgraded CRISPR Therapeutics (CRSP) from Market Perform to Underperform and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:24 pm

VRTX

HC Wainwright & Co. analyst Andrew Fein has maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $390 to $397.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:24 pm

NKE

Citigroup analyst Paul Lejuez has upgraded Nike (NYSE:NKE) from Neutral to Buy and increased the price target from $100 to $135, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:22 pm

FTRE

Citigroup analyst Patrick Donnelly upgraded Fortrea Holdings (NASDAQ: FTRE) from Neutral to Buy and increased the price target from $34 to $40.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:19 pm

WAT

Citigroup analyst Patrick Donnelly has maintained a Neutral rating on Waters Corporation (NYSE:WAT) and increased the price target from $265 to $300.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:15 pm

TMO

Citigroup analyst Patrick Donnelly has reaffirmed a Buy rating on Thermo Fisher Scientific (NYSE:TMO) and increased the price target from $530 to $575, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:13 pm

QDEL

Citigroup analyst Patrick Donnelly has downgraded QuidelOrtho (NASDAQ:QDEL) from Buy to Neutral and reduced the price target from $95 to $72.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:12 pm

DGX

Citigroup analyst Patrick Donnelly has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $130 to $145. This adjustment reflects Citigroup's updated valuation of the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:12 pm

OSUR

Citigroup analyst Patrick Donnelly has reaffirmed a Buy rating on OraSure Technologies (NASDAQ:OSUR) and increased the price target from $7 to $9.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:10 pm

MTD

Citigroup analyst Patrick Donnelly downgraded Mettler-Toledo Intl (MTD) from Neutral to Sell and reduced the price target from $1050 to $975.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:10 pm